JP2010516259A - ヒトがん幹細胞 - Google Patents

ヒトがん幹細胞 Download PDF

Info

Publication number
JP2010516259A
JP2010516259A JP2009546581A JP2009546581A JP2010516259A JP 2010516259 A JP2010516259 A JP 2010516259A JP 2009546581 A JP2009546581 A JP 2009546581A JP 2009546581 A JP2009546581 A JP 2009546581A JP 2010516259 A JP2010516259 A JP 2010516259A
Authority
JP
Japan
Prior art keywords
cancer stem
stem cells
cells
cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516259A5 (cg-RX-API-DMAC7.html
Inventor
ジェニー ピー． マサー
ペネロピ ロバーツ
Original Assignee
レイベン バイオテクノロジーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイベン バイオテクノロジーズ filed Critical レイベン バイオテクノロジーズ
Publication of JP2010516259A publication Critical patent/JP2010516259A/ja
Publication of JP2010516259A5 publication Critical patent/JP2010516259A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009546581A 2007-01-22 2008-01-22 ヒトがん幹細胞 Pending JP2010516259A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88149707P 2007-01-22 2007-01-22
US90718007P 2007-03-23 2007-03-23
US92424707P 2007-05-04 2007-05-04
US95071407P 2007-07-19 2007-07-19
US97261307P 2007-09-14 2007-09-14
PCT/US2008/051730 WO2008091908A2 (en) 2007-01-22 2008-01-22 Human cancer stem cells

Publications (2)

Publication Number Publication Date
JP2010516259A true JP2010516259A (ja) 2010-05-20
JP2010516259A5 JP2010516259A5 (cg-RX-API-DMAC7.html) 2010-12-24

Family

ID=39641454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546581A Pending JP2010516259A (ja) 2007-01-22 2008-01-22 ヒトがん幹細胞

Country Status (9)

Country Link
US (1) US8309354B2 (cg-RX-API-DMAC7.html)
EP (1) EP2109668A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010516259A (cg-RX-API-DMAC7.html)
KR (1) KR101523698B1 (cg-RX-API-DMAC7.html)
CN (1) CN101855339A (cg-RX-API-DMAC7.html)
AU (1) AU2008207945A1 (cg-RX-API-DMAC7.html)
CA (1) CA2675521C (cg-RX-API-DMAC7.html)
IL (1) IL199836A (cg-RX-API-DMAC7.html)
WO (1) WO2008091908A2 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046797A1 (ja) * 2010-10-06 2012-04-12 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞集団及びその作製方法
JP2013208104A (ja) * 2012-03-02 2013-10-10 Yamaguchi Univ 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
JP2015518561A (ja) * 2012-03-19 2015-07-02 ステムライン セラピューティクス，インコーポレーテッド 癌の状態を治療及びモニタリングする方法
JPWO2016170938A1 (ja) * 2015-04-20 2017-04-27 国立大学法人 岡山大学 がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法
JP2017528114A (ja) * 2014-06-25 2017-09-28 テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド がん幹細胞の同定ならびに診断および処置のためのその使用
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
CN108699529A (zh) * 2016-02-17 2018-10-23 普乐思尔活性生物科学有限公司 用于培养含癌症干细胞(csc)的细胞群的化学成分确定的培养基
JP2019213551A (ja) * 2013-08-12 2019-12-19 ミネルバ バイオテクノロジーズ コーポレーション 腫瘍成長を増強する方法
US10934351B2 (en) 2011-10-28 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
JP2022511607A (ja) * 2018-06-13 2022-02-01 北京基石生命科技有限公司 結腸直腸癌固形腫瘍初代細胞及び結腸直腸腺癌腹水初代腫瘍細胞の培養方法およびキット
JP2022546578A (ja) * 2019-09-04 2022-11-04 ブイセル セラピューティックス，インコーポレイテッド 癌を処置するためのワクチンおよびストレスリプログラミングによるその作製方法
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516259A (ja) 2007-01-22 2010-05-20 レイベン バイオテクノロジーズ ヒトがん幹細胞
JP5960946B2 (ja) * 2008-10-27 2016-08-02 北海道公立大学法人 札幌医科大学 がん幹細胞分子マーカー
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR20130055591A (ko) * 2010-04-13 2013-05-28 가부시키가이샤 르네상스 에너지 인베스트먼트 암 조직 유래 세포괴 또는 암 세포 응집괴로부터 얻어지는 암 치료용 조성물과 그것을 이용한 면역요법제의 제조 방법 및 면역요법 효과 평가 방법
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
KR20140031175A (ko) 2010-12-08 2014-03-12 스템 센트알엑스 인코포레이티드 신규 조절제 및 용법
KR101182549B1 (ko) * 2010-12-16 2012-09-12 엘지이노텍 주식회사 3차원 입체 카메라 모듈
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2689249B1 (en) * 2011-03-24 2016-05-25 The Rogosin Institute Assay for screening compounds that selectively decrease the number of cancer stem cells
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US10247731B2 (en) 2012-02-22 2019-04-02 Verik Bio, Inc. System for immunotherapy targeting tumor propagation and progression
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
WO2013126810A1 (en) 2012-02-24 2013-08-29 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
US10485858B2 (en) 2012-05-16 2019-11-26 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
WO2014165101A1 (en) * 2013-03-13 2014-10-09 California Stem Cell, Inc. Individualized high purity colon carcinoma stem cells, methods and use of the same
LT2958944T (lt) 2013-02-22 2019-07-10 Abbvie Stemcentrx Llc Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
CN105792836A (zh) 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
BR112016010169A2 (pt) 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
CN106550593A (zh) 2014-02-21 2017-03-29 艾伯维施特姆森特克斯有限责任公司 用于黑素瘤的抗‑dll3抗体和药物缀合物
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
FI3149045T3 (fi) 2014-05-27 2023-03-20 Academia Sinica Koostumuksia ja menetelmiä, jotka liittyvät yleisglykoformeihin vasta-aineiden parannettua tehokkuutta varten
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CN107430127B (zh) * 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
TW201805309A (zh) 2016-04-21 2018-02-16 艾伯維史坦森特瑞斯有限責任公司 新穎抗－bmpr1b抗體及使用方法
TWI764917B (zh) 2016-08-22 2022-05-21 醣基生醫股份有限公司 抗體、結合片段及使用方法
GB201700952D0 (en) * 2017-01-19 2017-03-08 Univ Cape Town In vitro propagation of primary cancer cells
CN107904206A (zh) * 2017-11-17 2018-04-13 张家港澳洋医院有限公司 一种脂多糖诱导肿瘤细胞生成肿瘤干细胞的用途和方法
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
CN109652377B (zh) * 2019-01-15 2023-03-28 广州医科大学 一种肺癌干细胞的制备方法及应用
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
CN113069547B (zh) * 2021-04-16 2023-01-24 同济大学附属第一妇婴保健院 Bap1作为肿瘤治疗靶点在制备预防或治疗肿瘤药物中的应用
CN113444690A (zh) * 2021-07-29 2021-09-28 大连大学 一种基于三维培养体系的肿瘤细胞耐照射模型的建立方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527211A (ja) * 2000-08-03 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 充実腫瘍幹細胞の単離及び用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050136066A1 (en) 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US7148038B2 (en) 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
EP1492566A4 (en) 2002-04-11 2005-11-23 Altarex Medical Corp BINDING AGENTS AND THEIR USE IN TARGETING TUMOR CELLS
JP4488512B2 (ja) 2002-06-19 2010-06-23 レイベン バイオテクノロジーズ，インコーポレイティド 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
KR20060076781A (ko) 2003-09-18 2006-07-04 레이븐 바이오테크놀로지스, 인코퍼레이티드 세포 배양 배지
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
JP4824025B2 (ja) 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
ITRM20040438A1 (it) 2004-09-15 2004-12-15 Univ Palermo Metodo per la purificazione e l'amplificazione di cellule staminali tumorali.
CA2998412C (en) 2004-11-12 2024-01-02 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
US7687242B2 (en) 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
CN101142236B (zh) 2005-02-02 2013-03-20 雷文生物技术公司 Adam-9调节剂
US20060171952A1 (en) 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
CA2597171A1 (en) 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Antibodies to oncostatin m receptor
MX2007009403A (es) 2005-02-04 2007-10-02 Raven Biotechnologies Inc Anticuerpos que se unen a epha2 y metodos para usar los mismos.
EP1907572A2 (en) * 2005-07-26 2008-04-09 Procure Therapeutics Limited Prostate stem cell markers
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
JP2010516259A (ja) 2007-01-22 2010-05-20 レイベン バイオテクノロジーズ ヒトがん幹細胞

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527211A (ja) * 2000-08-03 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 充実腫瘍幹細胞の単離及び用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012063271; 'Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ　ｏｆ　ＵＳＡ' ２００３，　Ｖｏｌ．１００，　Ｎｏ．７，　ｐｐ．３９８３-３９８８ *
JPN6012063273; 'Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ' ２００５，　Ｖｏｌ．６５，　Ｎｏ．２３，　ｐｐ．１０９４６-１０９５１ *
JPN6012063275; 'Ｎａｔｕｒｅ' １９９４，　Ｖｏｌ．３６７，　ｐｐ．６４５-６４８ *
JPN6012063278; 'Ｎａｔｕｒｅ　Ｒｅｖｉｅｗｓ　Ｃａｎｃｅｒ' ２００５，　Ｖｏｌ．５，　ｐｐ．３１１-３２１ *
JPN6012063281; 'Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ' ２００６，　Ｖｏｌ．６６，　Ｎｏ．２１，　ｐｐ．１０２４７-１０２５２ *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
WO2012046797A1 (ja) * 2010-10-06 2012-04-12 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞集団及びその作製方法
CN103328626A (zh) * 2010-10-06 2013-09-25 药物研究私人有限公司 癌干细胞群及其制备方法
JPWO2012046797A1 (ja) * 2010-10-06 2014-02-24 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞集団及びその作製方法
CN103328626B (zh) * 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
US11124773B2 (en) 2010-10-06 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell population and method for production thereof
JP2018029583A (ja) * 2010-10-06 2018-03-01 中外製薬株式会社 癌幹細胞集団及びその作製方法
US11965180B2 (en) 2010-10-06 2024-04-23 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell population and method for production thereof
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
US11858987B2 (en) 2011-10-28 2024-01-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
US10934351B2 (en) 2011-10-28 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
JP2013208104A (ja) * 2012-03-02 2013-10-10 Yamaguchi Univ 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
JP2015518561A (ja) * 2012-03-19 2015-07-02 ステムライン セラピューティクス，インコーポレーテッド 癌の状態を治療及びモニタリングする方法
JP2019213551A (ja) * 2013-08-12 2019-12-19 ミネルバ バイオテクノロジーズ コーポレーション 腫瘍成長を増強する方法
JP2017528114A (ja) * 2014-06-25 2017-09-28 テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド がん幹細胞の同定ならびに診断および処置のためのその使用
JP2017086091A (ja) * 2015-04-20 2017-05-25 国立大学法人 岡山大学 がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法
JPWO2016170938A1 (ja) * 2015-04-20 2017-04-27 国立大学法人 岡山大学 がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法
JP2019506878A (ja) * 2016-02-17 2019-03-14 プロモセル・バイオサイエンス・アライブ・ゲー・エム・ベー・ハー・ビオメディツィーニッシェ・プロドゥクテ がん幹細胞（ｃｓｃ）含有細胞集団の培養のための化学的に規定された培地
CN108699529B (zh) * 2016-02-17 2022-05-24 普乐思尔有限公司 用于培养含癌症干细胞(csc)的细胞群的化学成分确定的培养基
JP6990659B2 (ja) 2016-02-17 2022-01-12 プロモセル・ゲー・エム・ベー・ハー がん幹細胞（ｃｓｃ）含有細胞集団の培養のための化学的に規定された培地
CN108699529A (zh) * 2016-02-17 2018-10-23 普乐思尔活性生物科学有限公司 用于培养含癌症干细胞(csc)的细胞群的化学成分确定的培养基
JP2022511607A (ja) * 2018-06-13 2022-02-01 北京基石生命科技有限公司 結腸直腸癌固形腫瘍初代細胞及び結腸直腸腺癌腹水初代腫瘍細胞の培養方法およびキット
JP7507751B2 (ja) 2018-06-13 2024-06-28 北京基石生命科技有限公司 結腸直腸癌固形腫瘍初代細胞及び結腸直腸腺癌腹水初代腫瘍細胞の培養方法およびキット
JP2022546578A (ja) * 2019-09-04 2022-11-04 ブイセル セラピューティックス，インコーポレイテッド 癌を処置するためのワクチンおよびストレスリプログラミングによるその作製方法

Also Published As

Publication number Publication date
EP2109668A4 (en) 2011-10-05
EP2109668A2 (en) 2009-10-21
IL199836A (en) 2014-02-27
CA2675521C (en) 2016-04-26
AU2008207945A1 (en) 2008-07-31
WO2008091908A2 (en) 2008-07-31
WO2008091908A3 (en) 2009-12-30
IL199836A0 (en) 2010-04-15
US8309354B2 (en) 2012-11-13
US20080175870A1 (en) 2008-07-24
CA2675521A1 (en) 2008-07-31
CN101855339A (zh) 2010-10-06
KR20100033471A (ko) 2010-03-30
KR101523698B1 (ko) 2015-05-29

Similar Documents

Publication Publication Date Title
US8309354B2 (en) Human cancer stem cells
JP6207783B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
JP6630074B2 (ja) 新規に単離された細胞の治療組成物の操作および送達
JP6177735B2 (ja) 細胞傷害活性抗ｌａｇ−３モノクローナル抗体および臓器移植拒絶および自己免疫疾患の治療または予防における該抗体の使用方法
US6805869B2 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
WO2019024933A1 (zh) 靶向gpc3的car nk细胞
EP4426350A2 (en) Treatment of cancer with nk cells and multispecific engagers
TW202208616A (zh) 改良之腫瘤反應性ｔ細胞的選擇
KR20110025812A (ko) 세포독성 효과인자의 프라이밍을 차단하고 조절성 ｃｄ8+ ｔ 세포의 생성을 유도하는 항-ｃｄ8 항체
Chauvin et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats
US11701387B2 (en) Chimeric antigen receptor specific for BDCA2 antigen
WO2012064967A2 (en) Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
Baek et al. Dendritic cell (DC) vaccine in mouse lung cancer minimal residual model; comparison of monocyte-derived DC vs. hematopoietic stem cell derived-DC
WO2011060205A1 (en) Methods, compositions, and assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease
WO2022204564A2 (en) Methods and compositions for t-cell coculture potency assays and use with cell therapy products
US20140030276A1 (en) Cancer immunopotentiating agent containing rankl antagonist
WO2025096638A2 (en) Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
Jæhger Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy
JP2022544566A (ja) 不死化された筋芽細胞株及びその使用
Noda et al. Immunization with ASPH-loaded dendritic cells produces anti-tumor effects in a rat model of intrahepatic cholangiocarcinoma
Popple The tumour microenvironment influences antigen specific T cell transmigration
Gauldie et al. Dendritic Cells Derived from Murine Colonic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101105

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131010